---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060084"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:25:56.084263+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Renalytix enters $15M at-the-market equity offering with H.C. Wainwright

## Summary
- Company may sell ADSs with aggregate offering price up to $15M on Nasdaq through H.C. Wainwright.
- Placement fee of 3% of gross sales; company reimburses certain agent expenses.
- Agreement effective May 15, 2024; no obligation to sell any ADSs.

## SEC filing metadata
- accession: 0000950170-24-060084
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017024060084/0000950170-24-060084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017024060084/rnlx-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060084
- JSON: https://secwatch.observer/filing/0000950170-24-060084.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060084.txt

## Key facts
- Material Agreements
  Renalytix plc entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at up to $15 million (effective 2024-05-15).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: up to $15 million
  - Effective: 2024-05-15
  source text: On May 15, 2024, Renalytix plc (the “ Company ”) entered into an at the market offering agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (the “ Agent ”), pursuant to which the Company may issue and sell from time to time, at its option, the Company’s American Depositary Shares (the “ ADSs ”), each representing two ordinary shares (nominal value £0.0025 per share) of the Company, through or to the Agent, as sales agent and/or principal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017024060084/0000950170-24-060084-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.